Local 12, WCPO highlight brain tumor vaccine trial
Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor.
The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.
In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.
"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Improving treatment for deadly brain tumors
May 5, 2023
The University of Cincinnati's Soma Sengupta was a co-first author on research published in Cell Reports Medicine New that found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma, a deadly brain tumor.
Personalized immunotherapy to fight deadly brain tumors
April 13, 2023
The University of Cincinnati is enrolling patients in an Imvax study that will test the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
Local 12, WCPO highlight brain tumor vaccine trial
April 21, 2023
Local 12 and WCPO highlighted the Imvax trial being hosted at the University of Cincinnati that is testing the effectiveness of a personalized vaccine approach to fight deadly brain tumors.